{
  "ticker": "DNLI",
  "company_name": "Denali Therapeutics Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07328451",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE1",
      "condition": "Alzheimer Disease, Early Onset",
      "start_date": "2026-01",
      "completion_date": "2027-02",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT05450549",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Participant",
      "start_date": "2022-07-14",
      "completion_date": "2023-06-08",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT06281158",
      "title": "A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2024-03-01",
      "completion_date": "2024-04-30",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT05119790",
      "title": "A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2021-08-27",
      "completion_date": "2021-11-05",
      "enrollment": 0,
      "sponsor": "Biogen"
    },
    {
      "nct_id": "NCT05262023",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Frontotemporal Dementia",
      "start_date": "2022-02-01",
      "completion_date": "2028-11",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT05842941",
      "title": "HEALEY ALS Platform Trial - Regimen G DNL343",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Amyotrophic Lateral Sclerosis",
      "start_date": "2023-05-24",
      "completion_date": "2024-10-29",
      "enrollment": 0,
      "sponsor": "Merit E. Cudkowicz, MD"
    },
    {
      "nct_id": "NCT04551534",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2017-06-01",
      "completion_date": "2018-08-08",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT06181136",
      "title": "Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Mucopolysaccharidosis Type IIIA",
      "start_date": "2023-12-07",
      "completion_date": "2028-08",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT04251026",
      "title": "A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Mucopolysaccharidosis II",
      "start_date": "2020-07-16",
      "completion_date": "2031-02",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT06602193",
      "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Parkinson Disease",
      "start_date": "2024-10-24",
      "completion_date": "2028-02-28",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    }
  ],
  "summary": {
    "total_trials": 24,
    "by_phase": {
      "PHASE1": 13,
      "PHASE1, PHASE2": 3,
      "PHASE2, PHASE3": 3,
      "PHASE2": 2,
      "": 2,
      "PHASE3": 1
    },
    "by_status": {
      "NOT_YET_RECRUITING": 1,
      "COMPLETED": 14,
      "RECRUITING": 3,
      "ACTIVE_NOT_RECRUITING": 3,
      "ENROLLING_BY_INVITATION": 1,
      "TERMINATED": 2
    },
    "active_trials": 7,
    "completed_trials": 14,
    "conditions": [
      "Alzheimer Disease",
      "Alzheimer Disease, Early Onset",
      "Amyotrophic Lateral Sclerosis",
      "Frontotemporal Dementia",
      "Healthy Participant",
      "Healthy Volunteers",
      "Mucopolysaccharidosis II",
      "Mucopolysaccharidosis III-A",
      "Mucopolysaccharidosis Type IIIA",
      "Parkinson Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:02.076866",
    "search_query": "Denali Therapeutics Inc.",
    "url": "https://clinicaltrials.gov/search?term=Denali+Therapeutics+Inc."
  }
}